GlassScriptPhysician profile
Tatevik Mikaelyan
NPI 1881095925
$9,319.91
in general payments reported to CMS, 2019-2025
40 companies · $3,033 in 2025
The $3,033 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $980 · 2022: $686 · 2023: $2,161 · 2024: $2,460 · 2025: $3,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,584 · Education: $70.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,583.97 |
| Education | $70.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,563.31 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,483.73 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $925.79 | 2021-2025 | Trintellix |
| Novo Nordisk INC | $680.76 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $596.16 | 2021-2025 | |
| Axsome Therapeutics, INC. | $567.99 | 2023-2025 | Auvelity, Symbravo, Sunosi |
| Lundbeck LLC | $470.97 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $429.02 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $417.70 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $253.51 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $204.27 | 2024-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $185.84 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $163.22 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $148.61 | 2022-2025 | Quviviq, Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $123.63 | 2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tatevik Mikaelyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.